Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/targeting-p53-for-enhanced-radio-and-chemo-sensitivity-nOPfJBtRtF
References (128)
-
G. Selivanova, L. Ryabchenko, E. Jansson, V. Iotsova, K. Wiman (1999)
Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core DomainMolecular and Cellular Biology, 19
-
Roger Leng, Yunping Lin, Weili Ma, Hong Wu, B. Lemmers, S. Chung, J. Parant, G. Lozano, R. Hakem, S. Benchimol (2003)
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 DegradationCell, 112
-
Jian Yu, Zhenghe Wang, K. Kinzler, B. Vogelstein, Lin Zhang (2003)
PUMA mediates the apoptotic response to p53 in colorectal cancer cellsProceedings of the National Academy of Sciences of the United States of America, 100
-
Thomas Rippin, V. Bykov, S. Freund, G. Selivanova, K. Wiman, A. Fersht (2002)
Characterization of the p53-rescue drug CP-31398 in vitro and in living cellsOncogene, 21
-
E. Barbieri, P. Mehta, Zaowen Chen, Linna Zhang, A. Slack, S. Berg, J. Shohet (2006)
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell deathMolecular Cancer Therapeutics, 5
-
R. Magrini, D. Russo, L. Ottaggio, G. Fronza, A. Inga, P. Menichini (2008)
PRIMA‐1 synergizes with adriamycin to induce cell death in non‐small cell lung cancer cellsJournal of Cellular Biochemistry, 104
-
Yanhua Peng, Changgong Li, Lihong Chen, S. Sebti, Jiandong Chen (2003)
Rescue of mutant p53 transcription function by ellipticineOncogene, 22
-
À. Sierra, X. Castellsagué, A. Escobedo, B. Lloveras, M. García-Ramírez, A. Moreno, A. Fabra (2000)
Bcl‐2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancerInternational Journal of Cancer, 89
-
S. Lowe, S. Bodis, A. McClatchey, L. Remington, H. Ruley, D. Fisher, D. Housman, T. Jacks (1994)
p53 status and the efficacy of cancer therapy in vivo.Science, 266 5186
-
Hong Shen, Diarmuid Moran, C. Maki (2008)
Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.Cancer research, 68 20
-
Thomas Tan, G. Chu (2002)
p53 Binds and Activates the Xeroderma Pigmentosum DDB2 Gene in Humans but Not MiceMolecular and Cellular Biology, 22
-
A. Zeimet, C. Marth (2003)
Why did p53 gene therapy fail in ovarian cancer?The Lancet. Oncology, 4 7
-
W. El-Deiry (1998)
Regulation of p53 downstream genes.Seminars in cancer biology, 8 5
-
C. Schmitt, S. Lowe (2001)
Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo.Blood cells, molecules & diseases, 27 1
-
V. Bykov, N. Zache, H. Stridh, J. Westman, J. Bergman, G. Selivanova, K. Wiman (2005)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosisOncogene, 24
-
Zhao-hui Peng (2005)
Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.Human gene therapy, 16 9
-
Hiroshi Tanaka, H. Arakawa, Tatsuya Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei, Yusuke Nakamura (2000)
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damageNature, 404
-
G. Xu, I. Mawji, Chloe Macrae, C. Koch, A. Datti, J. Wrana, J. Dennis, A. Schimmer (2008)
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localizationApoptosis, 13
-
E. Snyder, Bryan Meade, C. Saenz, S. Dowdy (2004)
Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating PeptidePLoS Biology, 2
-
Man Jiang, Navjotsingh Pabla, R. Murphy, Tianxin Yang, Xiao-Ming Yin, K. Degenhardt, E. White, Z. Dong (2007)
Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation*Journal of Biological Chemistry, 282
-
Bin Wang, S. Matsuoka, P. Carpenter, S. Elledge (2002)
53BP1, a Mediator of the DNA Damage CheckpointScience, 298
-
Li Li, Binwei Deng, G. Xing, Y. Teng, Chunyan Tian, Xuan Cheng, Xiushan Yin, Juntao Yang, Xue Gao, Yun-ping Zhu, Qihong Sun, Lingqiang Zhang, Xiao Yang, F. He (2007)
PACT is a negative regulator of p53 and essential for cell growth and embryonic developmentProceedings of the National Academy of Sciences, 104
-
P. Secchiero, Carlotta Zerbinati, M. Iasio, E. Melloni, M. Tiribelli, V. Grill, G. Zauli (2007)
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.Current drug metabolism, 8 4
-
A. Yang, M. Kaghad, Yunmei Wang, Emily Gillett, M. Fleming, M. Fleming, M. Fleming, V. Dötsch, N. Andrews, N. Andrews, D. Caput, F. McKeon (1998)
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.Molecular cell, 2 3
-
J. Bischoff, D. Kirn, Angelica Williams, C. Heise, Sharon Horn, M. Muna, L. Ng, J. Nye, A. Sampson‐Johannes, A. Fattaey, F. McCormick (1996)
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 274
-
T. Hupp, A. Sparks, D. Lane (1995)
Small peptides activate the latent sequence-specific DNA binding function of p53Cell, 83
-
C. Tanikawa, K. Matsuda, S. Fukuda, Yusuke Nakamura, H. Arakawa (2003)
p53RDL1 regulates p53-dependent apoptosisNature Cell Biology, 5
-
T. Burns, W. El-Deiry (1999)
The p53 pathway and apoptosisJournal of Cellular Physiology, 181
-
E. Bassett, Wenge Wang, F. Rastinejad, W. El-Deiry (2008)
Structural and Functional Basis for Therapeutic Modulation of p53 SignalingClinical Cancer Research, 14
-
W. El-Deiry (2003)
The role of p53 in chemosensitivity and radiosensitivityOncogene, 22
-
F. Bunz, P. Hwang, C. Torrance, C. Torrance, T. Waldman, Yonggang Zhang, L. Dillehay, Jerry Williams, C. Lengauer, K. Kinzler, B. Vogelstein (1999)
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.The Journal of clinical investigation, 104 3
-
D. Bergamaschi, M. Gasco, L. Hiller, A. Sullivan, N. Syed, G. Trigiante, I. Yulug, M. Merlano, G. Numico, A. Comino, M. Attard, O. Reelfs, B. Gusterson, A. Bell, V. Heath, M. Tavassoli, P. Farrell, PaulR Smith, Xin Lu, T. Crook (2003)
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.Cancer cell, 3 4
-
S. Shangary, Shaomeng Wang (2008)
Targeting the MDM2-p53 Interaction for Cancer TherapyClinical Cancer Research, 14
-
M. Hamada, T. Fujiwara, A. Hizuta, A. Gochi, Y. Naomoto, N. Takakura, Kenji Takahashi, J. Roth, N. Tanaka, K. Orita (2005)
Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancersJournal of Cancer Research and Clinical Oncology, 122
-
WS El-Deiry (2003)
p53 downstream targets and chemosensitivityCell Death and Differentiation, 10
-
Wensheng Yang, W. El-Deiry (2007)
CARPs are E3 ligases that target apical caspases and p53Cancer Biology & Therapy, 6
-
Yin Li, Yuehua Mao, P. Brandt-rauf, A. Williams, R. Fine (2005)
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathwayMolecular Cancer Therapeutics, 4
-
Llorenç Coll‐Mulet, Daniel Iglesias-Serret, Antonio Santidrián, Ana Cosialls, M. Frías, E. Castaño, C. Campás, M. Barragán, A. Sevilla, A. Domingo, L. Vassilev, G. Pons, J. Gil (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.Blood, 107 10
-
R. Takimoto, T. Maclachlan, D. Dicker, Y. Niitsu, Toshio Mori, W. El-Deiry (2002)
BRCA1 Transcriptionally Regulates Damaged DNA Binding Protein (DDB2) In the DNA Repair Response Following UV-IrradiationCancer Biology & Therapy, 1
-
P. Fei, W. El-Deiry (2003)
P53 and radiation responsesOncogene, 22
-
H. Bell, C. Dufès, J. O'prey, D. Crighton, D. Bergamaschi, Xin Lu, A. Schätzlein, K. Vousden, K. Ryan (2007)
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.The Journal of clinical investigation, 117 4
-
H. Hermeking, Anne Benzinger (2006)
14-3-3 proteins in cell cycle regulation.Seminars in cancer biology, 16 3
-
P. Fei, Wenge Wang, Seok-Hyun Kim, Shulin Wang, T. Burns, Joanna Sax, M. Buzzai, D. Dicker, W. Mckenna, E. Bernhard, W. El-Deiry (2004)
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth.Cancer cell, 6 6
-
Wenge Wang, R. Takimoto, F. Rastinejad, W. El-Deiry (2003)
Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 BindingMolecular and Cellular Biology, 23
-
M. Gostissa, Arnd Hengstermann, V. Fogal, P. Sandy, Sylvia Schwarz, M. Scheffner, G. Sal (1999)
Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1The EMBO Journal, 18
-
Wenge Wang, W. El-Deiry (2008)
Restoration of p53 to limit tumor growthCurrent Opinion in Oncology, 20
-
R. Michelson, T. Weinert (1999)
Sensor-less checkpoint activation?Nature Cell Biology, 1
-
M. Blagosklonny, T. Fojo (1999)
Molecular effects of paclitaxel: Myths and reality (a critical review)International Journal of Cancer, 83
-
C. Cao, E. Shinohara, T. Subhawong, L. Geng, Kwang Kim, J. Albert, D. Hallahan, B. Lu (2006)
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2Molecular Cancer Therapeutics, 5
-
P. Komarov, E. Komarova, R. Kondratov, Konstantin Christov-Tselkov, J. Coon, M. Chernov, A. Gudkov (1999)
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.Science, 285 5434
-
Eri Oda, Rieko Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, N. Tanaka (2000)
Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.Science, 288 5468
-
M. Wei, W. Zong, E. Cheng, T. Lindsten, V. Panoutsakopoulou, Andrea Ross, K. Roth, G. MacGregor, C. Thompson, S. Korsmeyer (2001)
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 292
-
M. Kastan, A. Radin, S. Kuerbitz, O. Onyekwere, Cathy Wolkow, Curt Civin, Kelly Stone, T. Woo, Yaddanapudi Ravindranath, Ruth Craig (1991)
Levels of p53 protein increase with maturation in human hematopoietic cells.Cancer research, 51 16
-
L. Vassilev, B. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, Norman Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. Liu (2004)
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 303
-
A. Damalas, Sharon Kahan, M. Shtutman, A. Ben-Ze'ev, M. Oren (2001)
Deregulated β‐catenin induces a p53‐ and ARF‐dependent growth arrest and cooperates with Ras in transformationThe EMBO Journal, 20
-
C. Jost, M. Marin, W. Kaelin (1997)
p73 is a human p53-related protein that can induce apoptosisNature, 389
-
A. Børresen, T. Andersen, J. Eyfjörd, R. Cornelis, S. Thorlacius, Å. Borg, U. Johansson, C. Theillet, S. Scherneck, Susanne Hartman, C. Cornelisse, E. Hovig, P. Devilee (1995)
TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, 14
-
J. Kravchenko, G. Ilyinskaya, G. Ilyinskaya, Pavel Komarov, L. Agapova, D. Kochetkov, D. Kochetkov, Evguenia Strom, Elena Frolova, I. Kovriga, Andrei Gudkov, Elena Feinstein, P. Chumakov, P. Chumakov (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathwayProceedings of the National Academy of Sciences, 105
-
Yan Wang, J. Hailey, Denise Williams, Yaolin Wang, P. Lipari, M. Malkowski, Xiaoying Wang, Lei Xie, Guanghua Li, Deba Saha, Wai Ling, S. Cannon-Carlson, Robert Greenberg, R. Ramos, Robert Shields, L. Presta, P. Brams, W. Bishop, J. Pachter (2005)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibodyMolecular Cancer Therapeutics, 4
-
A. Shelling (1997)
Role of p53 in drug resistance in ovarian cancerThe Lancet, 349
-
Lijin Feng, Tongxiang Lin, Hiroaki Uranishi, W. Gu, Yang Xu (2005)
Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and ActivityMolecular and Cellular Biology, 25
-
J. Nemunaitis, S. Swisher, T. Timmons, D. Connors, Michael Mack, L. Doerksen, D. Weill, J. Wait, D. Lawrence, B. Kemp, F. Fossella, B. Glisson, W. Hong, F. Khuri, J. Kurie, J. Lee, Jangsoon Lee, D. Nguyen, J. Nesbitt, R. Perez-soler, K. Pisters, J. Putnam, W. Richli, D. Shin, G. Walsh, J. Merritt, J. Roth (2000)
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
-
Meiying Yang, S. Kroft, C. Chitambar (2007)
Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrateMolecular Cancer Therapeutics, 6
-
H. Graat, J. Carette, F. Schagen, L. Vassilev, W. Gerritsen, G. Kaspers, P. Wuisman, V. Beusechem (2007)
Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53Molecular Cancer Therapeutics, 6
-
Manel Esteller, S. Tórtola, Minoru Toyota, G. Capellá, M. Peinado, S. Baylin, James Herman (2000)
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.Cancer research, 60 1
-
N. Zache, Jeremy Lambert, K. Wiman, V. Bykov (2008)
PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 30
-
N. Issaeva, P. Bozko, M. Enge, Marina Protopopova, L. Verhoef, M. Masucci, A. Pramanik, G. Selivanova (2004)
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 10
-
C. Klein, L. Vassilev (2004)
Targeting the p53–MDM2 interaction to treat cancerBritish Journal of Cancer, 91
-
James Wilson (2005)
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of EditorialHuman Gene Therapy, 16
-
I. Ganly, I. Ganly, D. Kirn, S. Eckhardt, G. Rodriguez, D. Soutar, Randol Otto, A. Robertson, Oirhigh Park, Mark Gulley, C. Heise, D. Hoff, S. Kaye (2000)
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 3
-
B. Foster, Heather Coffey, M. Morin, F. Rastinejad (1999)
Pharmacological rescue of mutant p53 conformation and function.Science, 286 5449
-
D. Dornan, I. Wertz, Harumi Shimizu, D. Arnott, G. Frantz, P. Dowd, Karen Rourke, H. Koeppen, V. Dixit (2004)
The ubiquitin ligase COP1 is a critical negative regulator of p53Nature, 429
-
E. Komarova, M. Chernov, R. Franks, Kaihua Wang, G. Armin, C. Zelnick, D. Chin, S. Bacus, G. Stark, A. Gudkov (1997)
Transgenic mice with p53‐responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivoThe EMBO Journal, 16
-
C. Bakkenist, M. Kastan (2003)
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 421
-
C. Heise, A. Sampson‐Johannes, Angelica Williams, F. McCormick, D. Hoff, D. Kirn (1997)
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsNature Medicine, 3
-
D. Pritchard, A. Watson, C. Potten, A. Jackman, J. Hickman (1997)
Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation.Proceedings of the National Academy of Sciences of the United States of America, 94 5
-
Evguenia Strom, S. Sathe, P. Komarov, O. Chernova, Ivanda Pavlovska, Inna Shyshynova, D. Bosykh, L. Burdelya, R. Macklis, R. Skaliter, E. Komarova, A. Gudkov (2006)
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiationNature Chemical Biology, 2
-
A. Bode, Z. Dong (2004)
Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 4
-
Jie Zhou, T. Schmid, B. Brüne (2004)
HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation.Current molecular medicine, 4 7
-
Satoshi Inoue, R. Walewska, Martin Dyer, Gerry Cohen (2008)
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2Leukemia, 22
-
C. Preudhomme, P. Fenaux (1997)
THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIESBritish Journal of Haematology, 98
-
Shulin Wang, W. El-Deiry (2004)
The p53 pathway: targets for the development of novel cancer therapeutics.Cancer treatment and research, 119
-
W. El-Deiry, Harper Jw, O'Connor Pm, O'Connor Pm, V. Velculescu, C. Canman, C. Canman, J. Jackman, J. Pietenpol, M. Burrell, D. Hill, Yi-Song Wang (1994)
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.Cancer research, 54 5
-
Wenge Wang, W. El-Deiry (2004)
Targeting p53 by PTD-mediated transduction.Trends in biotechnology, 22 9
-
R. Takimoto, Wenge Wang, D. Dicker, F. Rastinejad, J. Lyssikatos, W. El-Deiry (2002)
The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce ApoptosisCancer Biology & Therapy, 1
-
Wenge Wang, Seok-Hyun Kim, W. El-Deiry (2006)
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.Proceedings of the National Academy of Sciences of the United States of America, 103 29
-
L. Crawford, D. Lane (1977)
An immune complex assay for SV40 T antigen.Biochemical and biophysical research communications, 74 1
-
P. Giannakakou, D. Sackett, Y. Ward, K. Webster, M. Blagosklonny, T. Fojo (2000)
p53 is associated with cellular microtubules and is transported to the nucleus by dyneinNature Cell Biology, 2
-
Xiuwei Tang, Yucui Zhu, Lydia Han, A. Kim, L. Kopelovich, D. Bickers, M. Athar (2007)
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.The Journal of clinical investigation, 117 12
-
Leming Shi, Timothy Myers, Yi Fan, P. O'Connor, K. Paull, S. Friend, S. Friend, J. Weinstein (1998)
Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.Molecular pharmacology, 53 2
-
L. Galluzzi, E. Morselli, O. Kepp, N. Tajeddine, G. Kroemer (2008)
Targeting p53 to mitochondria for cancer therapyCell Cycle, 7
-
K. Kojima, M. Konopleva, T. McQueen, S. O’Brien, W. Plunkett, M. Andreeff (2006)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.Blood, 108 3
-
P. Fei, E. Bernhard, W. El-Deiry (2002)
Tissue-specific induction of p53 targets in vivo.Cancer research, 62 24
-
V. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. Wiman, G. Selivanova (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 8
-
Ke Ding, Yipin Lu, Z. Nikolovska-Coleska, Guoping Wang, S. Qiu, S. Shangary, Wei-Lin Gao, Dongguang Qin, J. Stuckey, K. Krajewski, P. Roller, Shaomeng Wang (2006)
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.Journal of medicinal chemistry, 49 12
-
S. Supiot, Helen Zhao, K. Wiman, R. Hill, R. Bristow (2008)
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 86 3
-
Rutao Cui, H. Widlund, Erez Feige, Jennifer Lin, Dara Wilensky, Viven Igras, J. D'Orazio, C. Fung, C. Schanbacher, S. Granter, D. Fisher (2007)
Central Role of p53 in the Suntan Response and Pathologic HyperpigmentationCell, 128
-
N. Laurie, S. Donovan, C. Shih, Jiakun Zhang, Nicholas Mills, C. Fuller, A. Teunisse, S. Lam, Yolande Ramos, A. Mohan, Dianna Johnson, M. Wilson, C. Rodríguez-Galindo, M. Quarto, S. Francoz, S. Mendrysa, R. Guy, J. Marine, A. Jochemsen, M. Dyer (2006)
Inactivation of the p53 pathway in retinoblastomaNature, 444
-
Wenge Wang, W. Ho, D. Dicker, C. Mackinnon, J. Winkler, R. Marmorstein, W. El-Deiry (2005)
Acridine derivatives activate p53 and induce tumor cell death through baxCancer Biology & Therapy, 4
-
M. Irwin, K. Kondo, M. Marin, Lynn Cheng, W. Hahn, W. Kaelin (2003)
Chemosensitivity linked to p73 function.Cancer cell, 3 4
-
A. Friedler, L. Hansson, D. Veprintsev, S. Freund, Thomas Rippin, P. Nikolova, M. Proctor, S. Rüdiger, A. Fersht (2002)
A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutantsProceedings of the National Academy of Sciences of the United States of America, 99
-
R. Brachmann, Kexin Yu, Y. Eby, N. Pavletich, J. Boeke (1998)
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutationsThe EMBO Journal, 17
-
R Takimoto, W Wang, DT Dicker, F Rastinejad, J Lyssikatos, WS El-Deiry (2002)
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 proteinCancer Biol Ther, 1
-
JM Wilson (2005)
Gendicine: the first commercial gene therapy productHum Gene Ther, 16
-
K. Rogulski, S. Freytag, Kang Zhang, J. Gilbert, D. Paielli, J. Kim, C. Heise, D. Kirn (2000)
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.Cancer research, 60 5
-
C. Martins, L. Brown-Swigart, G. Evan (2006)
Modeling the Therapeutic Efficacy of p53 Restoration in TumorsCell, 127
-
S. Shangary, Dongguang Qin, D. McEachern, Meilan Liu, Rebecca Miller, S. Qiu, Z. Nikolovska-Coleska, Ke Ding, Guoping Wang, Jianyong Chen, D. Bernard, Jian Zhang, Yipin Lu, Q. Gu, R. Shah, K. Pienta, X. Ling, Sanmao Kang, M. Guo, Yi Sun, Dajun Yang, Shaomeng Wang (2008)
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 105
-
Wenge Wang, F. Rastinejad, W. El-Deiry (2003)
Restoring p53-Dependent Tumor SuppressionCancer Biology & Therapy, 2
-
W. Taylor, G. Stark (2001)
Regulation of the G2/M transition by p53Oncogene, 20
-
E. Sugikawa, T. Hosoi, N. Yazaki, M. Gamanuma, N. Nakanishi, M. Ohashi (1999)
Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.Anticancer research, 19 4B
-
T. Aas, A. Børresen, S. Geisler, B. Smith-Sørensen, H. Johnsen, J. Varhaug, L. Akslen, P. Lønning (1996)
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 2
-
F. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I. Tannock, L. Romel, M. Gore, J. Ironside, R. MacDougall, C. Heise, B. Randlev, A. Gillenwater, P. Bruso, S. Kaye, W. Hong, D. Kirn (2000)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancerNature Medicine, 6
-
A. Kim, A. Raffo, P. Brandt-rauf, M. Pincus, R. Monaco, P. Abarzúa, R. Fine (1999)
Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells*The Journal of Biological Chemistry, 274
-
Jun Tang, Like Qu, Jianke Zhang, Wenge Wang, J. Michaelson, Y. Degenhardt, W. El-Deiry, Xiaolu Yang (2006)
Critical role for Daxx in regulating Mdm2Nature Cell Biology, 8
-
N. Issaeva, A. Friedler, P. Bozko, K. Wiman, A. Fersht, G. Selivanova (2003)
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptideProceedings of the National Academy of Sciences of the United States of America, 100
-
A. Rehman, M. Chahal, Xiaoting Tang, J. Bruce, Y. Pommier, S. Daoud (2005)
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cellsBreast Cancer Research, 7
-
C. Heise, M. Lemmon, D. Kirn (2000)
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 12
-
S. Supiot, R. Hill, R. Bristow (2008)
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53Molecular Cancer Therapeutics, 7
-
H. Chan, N. Thangue (2001)
p300/CBP proteins: HATs for transcriptional bridges and scaffolds.Journal of cell science, 114 Pt 13
-
Marc Trielli, Paul Andreassen, Franqoise Lacroix, Robert Margolis (1996)
Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cellsThe Journal of Cell Biology, 135
-
Yang Xu (2003)
Regulation of p53 responses by post-translational modificationsCell Death and Differentiation, 10
-
E. Flores, Shomit Sengupta, John Miller, J. Newman, R. Bronson, D. Crowley, A. Yang, F. McKeon, T. Jacks (2005)
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.Cancer cell, 7 4
-
Y. Luu, J. Bush, K. Cheung, Gang Li (2002)
The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.Experimental cell research, 276 2
-
R. Edwards, N. Bentley, A. Carr (1999)
A Rad3–Rad26 complex responds to DNA damage independently of other checkpoint proteinsNature Cell Biology, 1
-
Marcin Krajewski, Przemysław Ozdowy, L. D'silva, U. Rothweiler, T. Holak (2005)
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitroNature Medicine, 11
-
Franklin Hutchinson (1985)
Chemical changes induced in DNA by ionizing radiation.Progress in nucleic acid research and molecular biology, 32
-
Dominique Kranz, M. Dobbelstein (2006)
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Cancer research, 66 21
-
H. Bell, K. Ryan (2007)
Targeting the p53 Family for Cancer Therapy: ‘Big Brother’ Joins the FightCell Cycle, 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2009 by Springer Science+Business Media, LLC
- Subject
- Biomedicine; Virology ; Biochemistry, general; Oncology ; Cell Biology; Cancer Research
- ISSN
- 1360-8185
- eISSN
- 1573-675X
- DOI
- 10.1007/s10495-009-0330-1
- pmid
- 19259822
- Publisher site
- See Article on Publisher Site
Abstract
p53 acts as a central mediator of the cellular response to stressful stimuli. The growth-suppressive function of p53 is lost with mutation and this occurs commonly in human cancer. In addition to suppressing cancer development and progression, wild-type p53 further confers chemo-sensitivity and radio-sensitivity upon tumor cells. Accumulated evidence over the last two decades that wild-type p53 activity is required for the efficacy of radiation and chemotherapy has led to considerable interest in development of strategies to restore normal p53 function in tumors with defective p53-dependent signaling. A number of promising discoveries, based on the knowledge of structural and functional basis of p53 mutation, p53 degradation by MDM2 and p53 family proteins, provide a foundation for future drug design. Here we review the role of p53 in enhancing the sensitivity from radiation and chemotherapy and discuss current progress on therapies targeting p53.
Journal
Apoptosis – Springer Journals
Published: Mar 4, 2009